What Галвус Treats: Main Uses and Benefits

The medication is commonly used to help address symptoms related to systemic imbalance in Type 2 Diabetes Mellitus. It is relevant for easing challenging manifestations like chronic high blood sugar (hyperglycemia), the noticeable spikes in glucose that follow meals, and the overall symptom cluster of inadequate glycemic control as reflected by elevated long-term average blood sugar (HbA1c).

The medication is applied in clinical settings that involve combining it with existing treatment plans, or used as a primary agent when initial therapy is insufficient or unsuitable. This supportive approach may assist with maintaining functional stability and moving toward established blood sugar goals, which generally helps patients cope more steadily with symptom fluctuations. The medication is applied when additional symptomatic support for management is appropriate.

Quick Fact: Relief for Systemic Imbalance Галвус is generally selected for its generally favorable profile, which assists with general well-being during symptomatic phases. It helps patients reach their blood sugar goals while also addressing symptomatic domains related to low blood sugar and medication-related weight changes.

---

Indications Summary: The medication is used to help manage Type 2 Diabetes Mellitus in situations involving a single agent or when supportive management alongside established treatments is needed.

Who can and cannot use Галвус?

The population eligibility for Галвус (Vildagliptin) is strictly defined by regulatory authorities based on age, existing medical conditions, and organ function. The medicine is approved for adults 18 years of age and above diagnosed with Type 2 Diabetes Mellitus. In older adults (ge 65 years), use is established, and no dosage adjustment is required.

---

Absolute Exclusions and Contraindications

Галвус must not be used in the following populations:

• Patients with known hypersensitivity to vildagliptin or any component of the tablet.
• Individuals with hepatic impairment (liver disease) or with pre-treatment elevated liver enzymes ( ALT or AST gt 2.5 x the upper limit of normal).
• Patients with Type 1 Diabetes Mellitus or diabetic ketoacidosis.

---

Restrictions and Limitations

Use is subject to limitations or not recommended for specific groups:

• Children and adolescents (lt 18 years) are not recommended due to safety and efficacy not being established in this age group.
• Patients with moderate or severe renal impairment or End Stage Renal Disease (ESRD) require a restricted maximum daily dose.
• Use is not recommended during pregnancy or breastfeeding due to a lack of sufficient human data.
• Patients with NYHA functional class IV heart failure are generally not recommended to use the medicine.

Interactions with other medicines and products

Галвус (vildagliptin) is generally associated with a low potential for clinically significant drug interactions. This is primarily due to its metabolic pathway, as it is largely eliminated by hydrolysis and does not significantly interact with or rely on the major Cytochrome P450 (CYP) enzyme system for metabolism.

Interacting Product Category	Interaction Mechanism / Resulting Constraint
Sulfonylureas (SU)	Combination increases the risk of hypoglycemia (low blood sugar). A lower dose of the co-administered Sulfonylurea may be considered to mitigate this risk.
ACE-Inhibitors	Co-administration is associated with a greater proportion of reported cases of angioedema (swelling of the face, lips, or throat). Caution is advised, and patients may require additional monitoring.
Hyperglycemic Agents	Medicines known to cause hyperglycemia (e.g., corticosteroids, thiazides, thyroid medicines) may reduce the glucose-lowering effect of vildagliptin, potentially requiring a dose alteration.

Absence of Clinically Relevant Interactions:

Pharmacokinetic studies found no clinically significant interactions when vildagliptin was co-administered with a number of common medications, including metformin, pioglitazone, amlodipine, digoxin, ramipril, simvastatin, valsartan, and warfarin. This suggests that vildagliptin does not affect the metabolism or clearance of these specific products.

Галвус (vildagliptin) operates as a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the rapid catabolism of endogenous incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Inhibition of DPP-4 by vildagliptin prevents the cleavage and inactivation of these incretins, resulting in elevated and sustained circulating concentrations of their active forms. This increase in active GLP-1 and GIP signaling modulates pancreatic islet function in a glucose-dependent manner.

The potentiated incretin action increases the glucose responsiveness of pancreatic beta cells, which leads to enhanced insulin secretion. Concurrently, the elevated incretin levels reduce the secretory capacity of pancreatic alpha cells, resulting in a corresponding decrease in glucagon secretion. This dual hormonal modulation—increased insulin release and suppressed glucagon release—regulates the homeostatic handling of glucose at a system level, particularly in the post-meal state. The mechanism is entirely dependent on the competitive binding and inactivation of the DPP-4 enzyme.

The use of Vildagliptin (Галвус) is based on a precise set of administration rules. This section describes the high-level, standardized approach to taking the medicine. The drug is supplied as an oral tablet and is intended for chronic, long-term management.

The total amount administered daily is either 50 mg or 100 mg, and the maximum dose authorized under all therapeutic regimens is 100 mg per day. The 100 mg daily dose may be taken as a single dose or split into two 50 mg doses taken in the morning and evening, a schedule often utilized when combined with certain other medications. The drug can be taken without regard to food, allowing flexibility in daily scheduling.

Instructions also outline modifications for specific populations:

Usage Constraint	Instruction
Route of Administration	Oral use, swallowed whole with a liquid.
Severe Renal Impairment	The recommended daily dose is reduced to 50 mg once daily.
Hepatic Impairment	The medicine is not recommended for use.
Older Adults (ge 65 years)	No specific dose adjustment is necessary.

If a scheduled dose is missed, it should be taken as soon as the patient remembers; however, patients are instructed not to take a double dose on the same day. These parameters define the procedural framework for Vildagliptin administration.

Research evidence / Overview of Studies for Vildagliptin (Галвус)

---

Evidence for Use as a Single Agent (Monotherapy)

The evidence base for using Vildagliptin as the only drug therapy for Type 2 Diabetes Mellitus primarily comes from multiple Randomized Controlled Trials (RCTs). These short- and intermediate-term studies were structured to explore how blood sugar levels, specifically the long-term average ( HbA1 c) and fasting glucose (FPG), change over defined time intervals. The research generally focused on adults who were newly diagnosed or had not yet started drug treatment, or those who met specific exclusion criteria related to other common initial treatments.

Studies monitored these glycemic outcomes over periods typically ranging from a few months up to one year, with some longer-term extensions documented. Findings describe the changes in HbA1 c measurements observed during the study period. Researchers also monitored outcomes related to physical discomfort and overall well-being. Reported observations regarding body weight in the monotherapy trials showed patterns related to minimal or small changes during the study period.

It is important to note that the research focuses primarily on measuring blood sugar status. Therefore, long-term effects on the durability of the response and non-glycemic outcomes are not well-characterized beyond the one-to-two-year timeframe. Comparative evidence against all other potential first-line therapies over extended periods remains a research gap.

---

Evidence for Use in Combination Therapy (Add-on Management)

A large part of the research effort has explored Vildagliptin when it is added to existing stable regimens, such as Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin therapy. These combination studies included multiple Randomized Controlled Trials (RCTs) alongside larger, real-world observational studies. Research examined patients whose blood sugar remained insufficiently monitored despite existing stable regimens, reflecting conditions where symptoms may vary in intensity.

The research examined changes in HbA1 c, Postprandial Glucose (PPG), and how often low blood sugar (hypoglycemia) was reported, particularly when Vildagliptin was studied with Sulphonylureas or Insulin. Studies monitored changes in the measured blood sugar biomarkers, and the findings describe patterns observed when Vildagliptin was added to these background therapies. Research provides insight into short-term changes, with these trials typically lasting between six months and one year.

Research provides context, but it does not determine whether an individual will respond similarly when Vildagliptin is combined with other medications. Although evidence for blood sugar-related outcomes is available for this approach, the research for certain newer combination partners is still emerging.

---

Long-Term Research and Durability of Effect

The available evidence includes data from studies that monitored patient responses over defined time intervals, with follow-up durations typically being intermediate-term (up to 2 years) for many regulatory submissions. These studies contribute to understanding what has been observed so far regarding the maintenance of blood sugar measurements and other physiological markers. Longer-term measurements and tolerability were observed in some follow-up studies and non-interventional post-marketing research.

While these findings contribute to the broader evidence landscape, there is limited information for long-term outcomes concerning the durability of Vildagliptin's effects beyond the two-year mark. Comparative evidence dedicated to extended outcomes, such as cardiovascular events, is lacking in the primary registration trials.

---

Evidence in Specific Patient Populations

Research has explored Vildagliptin in several specific groups who may present with functional limitations or other health challenges. For instance, Vildagliptin was studied for use in the elderly population (patients aged 65 years and older) with Type 2 Diabetes. Findings describe the measured changes in these studies, which generally included outcomes reflecting daily functioning or activity level.

Specific trials also included patients with moderate or severe kidney impairment to understand the drug’s use in conditions involving temporary physiological imbalance. These studies monitored outcomes related to physiological strain or stress. Research limitation frames indicate that data for certain groups, such as those with severe or unstable heart conditions (e.g., severe heart failure), remain insufficient because these patients were typically excluded from the main pivotal trials.

---

Research Gaps and Remaining Uncertainties

Although the evidence landscape is available regarding the short- to intermediate-term effects on core blood sugar markers, several areas are not fully established. Follow-up durations were limited in many primary trials, meaning there is limited information for very long-term outcomes regarding durability and patient well-being over decades.

Furthermore, results apply only to the populations studied. Data for certain groups, such as children and adolescents or patients with highly advanced and unstable health conditions, remain insufficient. Comparative evidence against all newer classes of antidiabetic agents is also currently lacking due to the timeline of the core research. Research provides context, but evidence highlights what is known—and what is still uncertain—about long-term implications for the specific populations studied.

Common questions about Галвус (FAQ)

Q: Is Galvus insulin or not?

A: Galvus (vildagliptin) belongs to a class of medicines called DPP-4 inhibitors. It is not insulin; instead, it works to support your body's natural production of insulin and is associated with a corresponding decrease in glucagon secretion, based on official product information.

Q: What should I do if I miss a dose of Galvus?

A: According to the official regulatory instructions, if a dose is missed, it should be taken as soon as a patient remembers. However, patients are instructed not to take a double dose on the same day to make up for the missed one.

Q: Does Galvus affect the liver?

A: Official documents indicate that rare cases of liver function disorders, including hepatitis, have been reported in connection with this medicine. Because of this, monitoring requires liver function tests to be performed before starting treatment and periodically throughout the first year.

Q: Can I drink coffee while taking Galvus?

A: Official instructions state that Galvus can be taken without regard to food. This flexibility in administration suggests that it can be taken with non-interacting beverages like coffee.

Q: What can happen if I suddenly stop taking Galvus?

A: Stopping any anti-diabetic medicine abruptly may lead to the return or worsening of high blood sugar levels, which is an expected clinical consequence. Any changes to the regimen should be managed by a healthcare professional.

Q: Can Galvus cause low sugar (hypoglycemia)?

A: Low blood sugar (hypoglycemia) is classified as a common side effect of vildagliptin. This risk is notably increased when the medication is used in combination with other diabetes treatments, such as sulfonylureas or insulin.

Q: How does Galvus interact with other diabetes medicines?

A: Regulatory documents note that combining Galvus with sulfonylureas increases the risk of hypoglycemia. However, pharmacokinetic studies found no clinically significant interactions when the drug was co-administered with medicines such as metformin or pioglitazone.

Q: How long should I take Galvus?

A: The medicine is officially intended for chronic, long-term management as part of the overall strategy for treating Type 2 Diabetes. The duration of therapy is established by the prescribing professional.

Q: Is Galvus a medication for lifelong use?

A: The medicine is classified for chronic, long-term management within the scope of Type 2 Diabetes treatment. The duration of use is defined by the individual treatment plan, consistent with the drug's intent for long-term management.

Q: Why do some people think Galvus is ineffective?

A: Official research documents indicate limited information for very long-term outcomes beyond the two-year mark. Furthermore, comparative evidence against all newer classes of anti-diabetic agents is limited, which contributes to the known research gaps.

Q: How are side effects from Galvus monitored and managed?

A: Official safety guidelines require regular monitoring, specifically liver function tests. Furthermore, adjustments to co-administered medicines, such as a reduced dose of sulfonylurea, may be required. The overall management of side effects is a clinical process handled by the prescribing professional.

Q: Are Galvus and Metformin the same thing?

A: No, Galvus (vildagliptin) and Metformin are different medicines belonging to different pharmacological classes. Vildagliptin is a DPP-4 inhibitor, while Metformin belongs to the biguanide class. They have different mechanisms of action for controlling blood sugar.

Q: What is the difference between Galvus and Galvus Met?

A: Galvus contains only the active substance vildagliptin. Galvus Met, by contrast, is a fixed-dose combination product containing both vildagliptin and metformin in a single tablet.

Q: How long until I see an effect from Galvus?

A: Research studies monitored changes in blood sugar markers, such as HbA1 c, over intermediate-term periods, typically starting within a few months. The actual timeframe for observed change may vary individually.

Q: Can I take Galvus once a day?

A: Official administration instructions state that the total maximum daily amount of 100 mg may be taken as a single dose. Alternatively, it can be split into two 50 mg doses, depending on the therapeutic regimen established for the patient.

Q: Should I take Galvus before, during, or after food?

A: According to the official product information, Galvus can be taken without regard to food. This provides flexibility in scheduling the daily intake.

Q: Can Galvus cause weight gain?

A: Clinical trials examining the use of vildagliptin alone (monotherapy) reported observations regarding body weight that showed patterns related to minimal or small changes during the study period.

Q: What are the most common side effects of Galvus?

A: Common reactions (occurring in ge 1/100 to < 1/10 individuals) listed in regulatory documents include dizziness, headache, and tremors. Hypoglycemia (low blood sugar) is also common, especially when the drug is used with sulfonylurea or insulin.

Q: Can Galvus cause stomach problems?

A: Official adverse reaction documents list constipation as an uncommon reaction (occurring in ge 1/1,000 to < 1/100 individuals). Acute pancreatitis has also been reported in post-marketing use.

Q: Can Galvus affect blood pressure?

A: The list of common or uncommon side effects does not explicitly include changes in high or low blood pressure. However, peripheral oedema (swelling) is listed as an uncommon reaction in official documents.

Q: Can I take Galvus if I take heart medications?

A: Pharmacokinetic studies found no clinically significant interactions when vildagliptin was co-administered with common heart and blood pressure medications, including amlodipine, digoxin, ramipril, and valsartan.

Q: Do I need to follow a special diet while taking Galvus?

A: Regulatory documentation specifies that Galvus is used in addition to diet and exercise. This highlights the importance of maintaining an appropriate lifestyle support program alongside the medication.

Q: Can I take Galvus during pregnancy?

A: Use of Galvus is not recommended during pregnancy. This constraint is based on the lack of sufficient human data to establish safety in this population.

Q: Can I take Galvus while breastfeeding?

A: Use of Galvus is not recommended while breastfeeding. This is a standard constraint applied due to the lack of sufficient human data regarding its presence in breast milk and safety for the infant.

Q: Why do doctors often prescribe Galvus instead of other drugs?

A: As a DPP-4 inhibitor, the drug is recognized for its mechanism of action, which modulates blood sugar in a glucose-dependent manner. Additionally, it is associated with a low potential for clinically significant drug interactions, which may be a factor in treatment selection.

Q: What research confirms the action of Galvus?

A: The evidence base that defines the drug's action consists primarily of Randomized Controlled Trials (RCTs) and observational studies. This research explored and measured outcomes related to blood sugar markers, such as long-term averages ( HbA1 c).

Q: Is Galvus an original drug or a generic?

A: Galvus is the trade name for vildagliptin. It is the original drug originally developed and manufactured by Novartis, the original developer.

Q: Can I take Galvus if I have a history of pancreatitis?

A: Post-marketing reports have documented cases of acute pancreatitis, though the frequency cannot be estimated from available data. Suitability in the context of personal medical history is subject to clinical evaluation.

Q: What is described in official documents as the benefit of Galvus?

A: The general purpose of the drug, as described in official documents, is to support and stabilize glycemic control in adults diagnosed with Type 2 Diabetes Mellitus.

Q: What patient groups most often use Galvus?

A: The medication is approved for use in adults 18 years of age and older. Research has specifically established its use in older adults (ge 65 years) and in patients with chronic kidney impairment (use is subject to official limitations for that group).

Q: Is there data on the long-term effects of Galvus?

A: Available evidence includes data from studies that monitored patient responses over follow-up durations typically up to two years. Official documents note that information on very long-term outcomes, spanning decades, is limited.

Q: Can Galvus affect driving a car?

A: Official warnings exist because of the potential for certain side effects, such as dizziness and tremor, which could affect the ability to drive or operate machinery. The official warnings relate to these potential effects.

Q: Where can I read the official instructions for Galvus?

A: Official regulatory information can be found in the Patient Information Leaflet (PIL) that comes with the medicine, as well as in the professional prescribing document (Summary of Product Characteristics or SmPC) published by regulatory agencies.

Q: What is known about the use of Galvus in children?

A: The use of Galvus is not recommended in children and adolescents under 18 years of age. This restriction is because safety and efficacy have not been established in this younger age group through clinical trials.

Q: Are there restrictions on taking Galvus for certain types of work?

A: Official restrictions relate to activities that require high levels of concentration and coordination. This warning is related to the potential for side effects, such as dizziness or tremor, as noted in the official warnings regarding operating machinery.

How to Store and Dispose of Galvus (Vildagliptin)

Storage Requirements

Official regulatory guidelines require Galvus tablets to be stored in the original package (blister) to ensure protection from moisture. The product label states that no special temperature storage conditions are required, meaning it is stable when stored at normal ambient conditions. Consistent with general safety standards, the medication must be kept out of the sight and reach of children at all times.

Disposal Instructions

To dispose of expired or unused Galvus tablets, individuals must follow the local requirements and utilize the appropriate local systems established for pharmaceutical waste. The medication should not be discarded via household trash or wastewater unless specifically instructed to do so by a healthcare professional or the authorized disposal program.